Benchmarking the New ESGO Standards: Hegongkang® CISCER® Uses International Strength to Solve the 'Triage Challenge' in Cervical Cancer Screening

August 6, 2026, 16:42

The European Society of Gynaecological Oncology (ESGO) and the European Network of Gynaecological Advocacy Groups (ENGAGe) recently released a landmark Position Statement on Risk-Based Cervical Cancer Screening, systematically proposing 7 core recommendations for the first time and moving the global screening strategy from a "one-size-fits-all" approach into the era of "risk stratification." Notably, the statement emphasizes "screening protocols individually designed according to the inherent risk of target populations" and "management of precancerous lesions adjusted by HPV type and carcinogenic potential," placing unprecedented demands on triage technologies.

I. Hegongkang® CISCER® Practices Molecular Triage

Against this international backdrop, Beijing Origin-Poly's Hegongkang® CISCER® stands out with its deep international presence. The product holds both China's NMPA Class III certification and EU CE certification, and has supported the publication of nearly 20 international SCI papers and numerous presentations at international conferences. CISCER®, based on PAX1/JAM3 dual-gene methylation technology, is a perfect practitioner of the "molecular triage" concept advocated in the ESGO statement.

Clinical data show that CISCER® can precisely identify high-risk patients, reducing unnecessary colposcopy referral rates in HR-HPV positive populations by 44.5% compared with traditional cytology, while ensuring an extremely high safety profile with CIN3+ risk as low as 0.9% in CISCER-negative populations. In particular, among postmenopausal women and populations infected with non-HPV16/18 types, its AUC reaches 0.934, effectively resolving the dual clinical pain points of "missed diagnosis" and "over-treatment."

With the implementation of the new ESGO standards, this "domestic precision tool" benchmarked against international standards is becoming a key element in achieving precise management of secondary prevention of cervical cancer, helping accelerate the global strategy to eliminate cervical cancer.

II. Key Points of the Position Statement on Risk-Based Cervical Cancer Screening and Problem Solving

Why is the "old logic" no longer sufficient?

The familiar pathway over the past decades was: regular TCT or HPV testing starting at ≥30 years of age → if HPV positive, look at cytology → if clearly abnormal, refer to colposcopy. This model drove the success of the "two-cancer screening" programs, but several old problems are increasingly unavoidable:

·For the same HPV positivity, can the risk of persistent HPV16 positivity and a one-time positive result for other high-risk types really be the same?

·Should screening intervals be the same for vaccinated people and those never vaccinated?

·Should management strategies be the same for CIN2 in young women and persistent HPV16 positivity in older women?

The answer to all is "no."

This time, ESGO/ENGAGe provide 7 core recommendations:

1. HPV DNA testing as the primary primary-screening method for secondary prevention of cervical cancer

2. Support gender-neutral HPV vaccination to accelerate the elimination of cervical cancer

3. Two-way communication between screening institutions and clinicians to identify high-risk individuals by vaccination history/screening history/participation

4. Screening protocols individually designed according to the inherent risk of target populations

5. Management of precancerous lesions adjusted by HPV type and carcinogenic potential

6. Self-sampling + HPV DNA testing to increase screening participation

7. Attention to the psychological and communication issues caused by HPV infection and screening

Source

Joura E, Chatzistamatiou K, Gultekin M, et al. European Society of Gynaecological Oncology/European Network of Gynaecological Advocacy Groups Position on risk-based cervical cancer screening. Int J Gynecol Cancer. doi:10.1016/j.ijgc.2026.104794

About CISPOLY

CISPOLY · Beijing Origin-Poly

Beijing Origin-Poly Co., Ltd. is a technology enterprise driven by innovation and dedicated to health. As a pioneer in early diagnosis of gynecologic tumors, CISPOLY has developed early-diagnosis products for cervical, endometrial, and ovarian cancers using proprietary technologies and patent-protected biomarkers, filling a gap in the field. As women pay increasing attention to their own health, the women's health market holds great potential. Beyond the gynecologic tumor early screening and early diagnosis product line, CISPOLY will continue to build more women's health-related product pipelines, establishing itself as a technology-innovative leading enterprise in the women's health market.